Long term treatment of multiple sclerosis with interferon-β may be cost effective

PharmacoEconomics

Volumn 18, Issue 1, 2000, Pages 45-53

  Kendrick, Malcolm ^a   Johnson, K Ian ^a  

^a The Towers   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HUMAN; LONG TERM CARE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

EID: 0033911466     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018010-00005     Document Type: Review

References (17)

1. 1. Nicholson T, Milne R. Beta interferons (1a and 1b) in relapsing-remitting and secondary progressive multiple sclerosis. Development and Evaluation Committee Report No. 98. Southampton: Wessex Institute for Health Research and Development, 1999
2. 2. Parkin D, McNamee P, Jacoby A, et al. A cost-utility analysis of interferon beta for multiple sclerosis. Health Technol Assessment 1998; 2 (4): iii-54
3. 3. Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13: 607-22
4. 4. Forbes RB, Lees A, Waugh W, et al. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999; 319: 1529-33
5. 5. Arnason BG, Dayal A, Qu ZX, et al. Mechanism of action of interferon-β in multiple sclerosis. Semin Immunopathol 1996; 18: 125-48
6. 6. Trapp BD, Ransohoff RM, Fisher E, et al. Neurodegeneration in multiple sclerosis: relationship to neurological disability. Neuroscientist 1999; 5: 48-57
7. 7. Bradley WG. Recent views on amyotrophic lateral sclerosis with emphasis on electrophysiological studies. Muscle Nerve 1998; 10:490-502
8. 8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52
9. 9. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989; 112: 133-46
10. 10. Rudick RA, Fisher E, Lee J-C, et al. The impact of interferon beta-1a on progressive brain atrophy in patients with relapsing multiple sclerosis. Neurology 1999; 53: 1698-704
11. 11. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis: the Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-94
12. 12. Whetten-Goldstein K, Sloan FA, Goldstein LB, etal. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4: 419-25
13. 13. Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95: 268-74
14. 14. Holmes J, Madgwick T, Bates D. The cost of multiple sclerosis. Br J Med Econ 1995; 8: 181-93
15. 15. Bourdette DN, Prochazka AV, Mitchell W, et al. Health care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA MS Rehabilitation Study Group. Arch Phys Med Rehabil 1993; 74: 26-31
16. 16. EUROQOL Group. EuroQol: a new facility for the measurement of health related quality of life. Health Policy 1990; 16: 199-208
17. 17. Liu C, Blumhardt LD. Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves. J Neurol Neurosurg Psychiatry 1999; 67: 451-6